Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis

Arch Dermatol. 2012 Apr;148(4):539-41. doi: 10.1001/archdermatol.2011.1399.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Comparative Effectiveness Research*
  • Dermatology / statistics & numerical data*
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Methotrexate / therapeutic use
  • Psoriasis / drug therapy*
  • Psoriasis / radiotherapy
  • Randomized Controlled Trials as Topic*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Ustekinumab

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Ustekinumab
  • Adalimumab
  • Etanercept
  • Methotrexate